Short-term and long-term cardiovascular actions of different doses of perindopril in the rabbit

Pharmacological Research

Volumn 34, Issue 3-4, 1996, Pages 135-141

  Fennessy, Paul A ^b   Godwin, Shirley ^a   Head, Geoffrey A ^a   Campbell, Julie H ^b   Campbell, Gordon R ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

ACE inhibitors; Blood pressure; Heart rate; Perindopril

Indexed keywords

ANGIOTENSIN I; DIPEPTIDYL CARBOXYPEPTIDASE; PERINDOPRIL; PERINDOPRILAT;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME INHIBITION; HEART RATE; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; TREATMENT OUTCOME;

EID: 0030239441     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0078     Document Type: Article

References (32)

1. 1. Todd PA, Fitton A. Perindopril: A review of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42: 90-114.
2. 2. Jackson B, Cubela R, Johnston CI. Angiotensin-converting enzyme inhibitors: measurement of relative inhibitory potency and serum drug levels by radio inhibitor binding displacement assay. J Cardiovasc Pharmacol 1987; 9: 699-704.
3. 3. Forette F, McClaran J, Delasalle MC, Hervy MP, Bouchacourt P, Henry-Amar M, Santoni JP. Value of angiotensin converting enzyme inhibitors in the elderly: the example of perindopril. Clin Exp Hypertens [A] 1989; 11: 587-603.
4. 4. Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study. Clin Exp Hypertens[A] 1989; A11: 575-86.
5. 5. Unger T, Gohlke P, Gruber M-G. Converting enzyme inhibitors. In: Ganten D, Mulrow PJ, eds. Pharmacology of anti-hypertensive therapeutics. Berlin: Springer-Verlag, 1990: 377-481.
6. 6. Weich HFH, Commerford PJ. ACE inhibitors prevent post-infarction arrhythmias and reinfarction. S Afr Med J 1991; 80: 14-7.
7. 7. Campbell BC, Shepherd AN, Reid JL. Effects of angiotensin-converting enzyme inhibitor, captopril, in essential hypertension. Br J Clin Pharmacol 1982; 13: 213-7.
8. 8. Jackson B, McGrath BP, Johnston CI. Correlation between angiotensin-converting enzyme inhibition and the acute hypotensive response to MK-421 in essential hypertension. Clin Exper Pharmacol Physiol 1982; 9: 99-104.
9. 9. Johnston CI, Jackson B, McGrath B, Matthews G, Arnolda L. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin-converting enzyme inhibition. J Hypertens 1983; 1: 71-5.
10. 10. Jouquey S, Stepniewski JP, Hamon G. Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol 1994; 23: 16-8.
11. 11. Kaplan HR, Cohen DM, Essenburgh AD. CI-906 and CI-907: new orally active nonsulfhydryl angiotensin-converting enzyme inhibitors. Fed Proc 1984; 43: 1326-9.
12. 12. Ohmura I, Maki E, Naruse T. Correlation between inhibition of the renin angiotensin system and the antihypertensive effect of MK-421 and captopril in 2-kidney, 1-clip renal hypertensive rats after single and repeated oral administration of MK-421 or captopril. Folia Pharmacol 1985; 86: 303-13.
13. 13. Aono J, Koga T, Yamazaki T, Shiraki Y, Sakai K. Antihypertensive action of a novel orally active angiotensin-converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril. Pharmacodyn Ther 1988; 292: 203-22.
14. 14. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Anti-atherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31.
15. 15. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in Cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: 565-72.
16. 16. Jacobsson LS, Persson K, Aberg G, Andersson RGG, Karlberg BE, Olsson AG. Antiatherosclerotic effects of the angiotensin-converting enzyme inhibitors captopril and fosinopril in hypercholesterolemic minipigs. J Cardiovasc Pharmacol 1994; 24: 670-7.
17. 17. Miyazaki M, Song K, Ishii K, Okunishi H, Ikeno A, Okazaki Y, Hosoki K. Vascular angiotensin converting enzyme in cholesterol-fed monkeys and anti-atherosclerotic property of an angiotensin converting enzyme inhibitor, alacepril. Third International Symposium on ACE Inhibition 1993; Amsterdam; Abstract 7: 4.
18. 18. Overturf M, Sybers H, Schaper J, Taegtmeyer H. Hypertension and atherosclerosis in cholesterol-fed rabbits. I. Mild, two-kidney, one clip Goldblatt hypertension treated with enalapril. Atherosclerosis 198?; 59: 283-99.
19. 19. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994; 106: 29-41.
20. 20. Sato K, Chatani F, Sato S. Circadian and short-term variabilities in blood pressure and heart rate measured by telemetry in rabbits and rats. J Auton Nerv Syst 1995; 54: 235-46.
21. 21. Woods RL, Anderson WP. Atrial natriuretic peptide infusion causes vasoconstriction after autonomic blockade in conscious dogs. Am J Physiol 1990; 259: R813-22.
22. 22. Cushman CW, Cheung HS. Spectrophotometric assay and properties of the angiotensin converting enzyme of rabbit lung. Biochem Pharmacol 1971; 20: 1637-48.
23. 23. van den Berg H, Resplandy G, de Bie AT, Floor W, Bertrand M, Arts CJ. A new radioimmunoassay for the determination of the angiotensin-converting enzyme inhibitor Perindopril and its active metabolite in plasma and urine: advantages of a lysine derivative as immunogen to improve the assay specificity. J Pharmacol Biomed Anal 1991; 9: 517-24
24. 24. Snedecor GW, Cochran WG. Statistical methods, 8th Ed, Ames: Iowa State University Press; 1989: p 503.
25. 25. Dzau VJ. Short- and long-term determinants of cardiovascular function and therapy: contribution of circulating and tissue renin-angiotensin systems. J Cardiovasc Pharmacol 1989; 14: 1-5.
26. 26. Ferrario CM. The renin-angiotensin system: importance in physiology and pathology. J Cardiovasc Pharmacol 1990; 15: 1-5.
27. 27. Marin J. Mechanisms involved in the increased vascular resistance in hypertension. J Auton Pharmacol 1993; 13: 127-76.
28. 28. Brunner HR, Nussberger J, Waeber B. Effects of angiotensin converting enzyme inhibition: a clinical point of view. J Cardiovasc Pharmacol 1985; 7: 73-81.
29. 29. Fyrquist F. Clinical pharmacology of the ACE inhibitors. Drugs 1986; 32: 33-9.
30. 30. Johnston CI, Clappison BH, Anderson WP, Yasujima M. Effects of angiotensin-converting inhibition on circulating and local kinin levels. Am J Cardiol 1982; 49: 1401-4.
31. 31. Ogihara T, Maruyama A, Hata T, Mikami H, Nakamura M, Naka T, Ohde H, Kumahara Y. Hormonal responses to long-term converting enzyme inhibition in hypertensive patients. Clin Pharmacol Ther 1981; 30: 328-35.
32. 32. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. Clin Exp Hypertens [A] 1992; 14: 307-31.